Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia

ABSTRACT Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytokine release syndrome (CRS) and neurological toxicities (ICANS). This manuscript aims to provide a consensus of specialists in the fields of Hema- tology Oncology and Cellular Therapy to make recommendations on the current scenario of the use of CAR-T cells in patients with ALL.

Saved in:
Bibliographic Details
Main Authors: Seber,Adriana, Castro Junior,Claudio Galvãode de, Kerbauy,Lucila N, Hirayama,Alexandre V, Bonfim,Carmem, Fernandes,Juliana Folloni, Souza,Mair, Schafell,Rony, Nabhan,Samir, Loggetto,Sandra Regina, Simões,Belinda Pinto, Rocha,Vanderson, Lima,Marcos de, Guerino-Cunha,Renato L, Bittencourt,Henrique
Format: Digital revista
Language:English
Published: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) 2021
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792021000500013
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytokine release syndrome (CRS) and neurological toxicities (ICANS). This manuscript aims to provide a consensus of specialists in the fields of Hema- tology Oncology and Cellular Therapy to make recommendations on the current scenario of the use of CAR-T cells in patients with ALL.

Similar Items